GSE184295
Polo-like kinase 1 inhibitors differentiate triple-negative breast cancer towards a luminal cell fate
Transcriptomic profiling was applied to investigate the effects of polo-like kinase 1 inhibition in triple-negative breast cancer. Overall design: SUM149PT cells were treated in vitro with rigosertib for 3 days with or without the supplementation of estradiol.